Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Oseltamivir (Tamiflu®) is recommended for use within NHS Wales for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. |
|||
|
|||
Medicine details |
|||
| Medicine name | oseltamivir (Tamiflu®) | ||
| Formulation | 30 mg, 45 mg, 75 mg capsule; 6 mg/ml powder for oral suspension | ||
| Reference number | 2800 | ||
| Indication | Treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community |
||
| Company | Roche Products Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0316 | ||
| NMG meeting date | 20/01/2016 | ||
| AWMSG meeting date | 24/02/2016 | ||
| Ratification by Welsh Government | 24/03/2016 | ||
| Date of issue | 01/04/2016 | ||
| Date of last review | 02/04/2019 | ||